| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 73 | 2021 | 1127 | 10.440 |
Why?
|
| Ischemic Attack, Transient | 14 | 2019 | 90 | 4.930 |
Why?
|
| Brain Ischemia | 26 | 2020 | 399 | 3.980 |
Why?
|
| Fibrinolytic Agents | 15 | 2020 | 163 | 2.350 |
Why?
|
| Tissue Plasminogen Activator | 16 | 2020 | 125 | 2.160 |
Why?
|
| Thrombolytic Therapy | 11 | 2020 | 184 | 1.560 |
Why?
|
| Cerebral Hemorrhage | 8 | 2021 | 85 | 1.490 |
Why?
|
| Atrial Fibrillation | 11 | 2020 | 805 | 1.400 |
Why?
|
| Stroke Rehabilitation | 5 | 2021 | 46 | 1.310 |
Why?
|
| Brain | 14 | 2024 | 1488 | 1.290 |
Why?
|
| Humans | 108 | 2025 | 59360 | 1.180 |
Why?
|
| Secondary Prevention | 4 | 2017 | 151 | 1.100 |
Why?
|
| Middle Cerebral Artery | 4 | 2017 | 46 | 1.090 |
Why?
|
| Hypertension | 8 | 2017 | 568 | 1.070 |
Why?
|
| Aged | 50 | 2021 | 13416 | 1.000 |
Why?
|
| Thrombectomy | 2 | 2019 | 208 | 0.980 |
Why?
|
| Antihypertensive Agents | 4 | 2016 | 162 | 0.940 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2024 | 11 | 0.910 |
Why?
|
| Cerebrovascular Disorders | 4 | 2018 | 74 | 0.900 |
Why?
|
| Female | 62 | 2021 | 30705 | 0.890 |
Why?
|
| Organoids | 1 | 2024 | 40 | 0.890 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2014 | 211 | 0.870 |
Why?
|
| Male | 56 | 2021 | 27739 | 0.840 |
Why?
|
| Motor Neuron Disease | 1 | 2023 | 28 | 0.830 |
Why?
|
| Hematoma | 3 | 2019 | 68 | 0.800 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2016 | 8 | 0.790 |
Why?
|
| Blood Pressure | 3 | 2016 | 495 | 0.750 |
Why?
|
| Middle Aged | 46 | 2021 | 16317 | 0.740 |
Why?
|
| Treatment Outcome | 28 | 2020 | 5284 | 0.710 |
Why?
|
| Endovascular Procedures | 3 | 2016 | 608 | 0.710 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 255 | 0.680 |
Why?
|
| Aged, 80 and over | 24 | 2021 | 5128 | 0.670 |
Why?
|
| Bed Rest | 1 | 2019 | 10 | 0.670 |
Why?
|
| Myxoma | 1 | 2019 | 13 | 0.660 |
Why?
|
| Risk Factors | 25 | 2020 | 4984 | 0.660 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2016 | 1526 | 0.640 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 1479 | 0.630 |
Why?
|
| Time Factors | 22 | 2020 | 3617 | 0.630 |
Why?
|
| Retrospective Studies | 22 | 2020 | 6071 | 0.630 |
Why?
|
| Piperazines | 3 | 2025 | 74 | 0.620 |
Why?
|
| Telemedicine | 2 | 2023 | 307 | 0.620 |
Why?
|
| Carotid Stenosis | 4 | 2014 | 104 | 0.610 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2017 | 40 | 0.600 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2021 | 2060 | 0.590 |
Why?
|
| Infarction, Middle Cerebral Artery | 2 | 2017 | 70 | 0.580 |
Why?
|
| Emergency Service, Hospital | 2 | 2016 | 1021 | 0.560 |
Why?
|
| Concurrent Review | 1 | 2017 | 3 | 0.560 |
Why?
|
| Length of Stay | 4 | 2020 | 775 | 0.560 |
Why?
|
| Triage | 2 | 2016 | 109 | 0.550 |
Why?
|
| Ticlopidine | 2 | 2014 | 45 | 0.540 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 31 | 0.530 |
Why?
|
| Teaching | 2 | 2008 | 152 | 0.530 |
Why?
|
| Virtual Reality | 1 | 2016 | 12 | 0.520 |
Why?
|
| Thalamic Diseases | 1 | 2016 | 2 | 0.520 |
Why?
|
| Primary Prevention | 1 | 2017 | 134 | 0.510 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2016 | 24 | 0.500 |
Why?
|
| Aspirin | 2 | 2014 | 166 | 0.500 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 687 | 0.490 |
Why?
|
| Postmenopause | 4 | 2021 | 224 | 0.470 |
Why?
|
| Quality of Health Care | 2 | 2020 | 510 | 0.460 |
Why?
|
| Feedback, Psychological | 1 | 2014 | 11 | 0.460 |
Why?
|
| Occupational Therapy | 1 | 2014 | 12 | 0.450 |
Why?
|
| Speech Therapy | 1 | 2014 | 15 | 0.450 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 45 | 0.440 |
Why?
|
| Dipyridamole | 1 | 2013 | 17 | 0.440 |
Why?
|
| Smoking | 4 | 2018 | 826 | 0.440 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 735 | 0.430 |
Why?
|
| Endarterectomy, Carotid | 2 | 2012 | 91 | 0.430 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2013 | 10 | 0.430 |
Why?
|
| Healthcare Disparities | 3 | 2020 | 326 | 0.420 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 129 | 0.420 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 192 | 0.410 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 205 | 0.410 |
Why?
|
| Dementia, Multi-Infarct | 1 | 2012 | 4 | 0.410 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2012 | 2 | 0.410 |
Why?
|
| Quality Improvement | 1 | 2017 | 416 | 0.400 |
Why?
|
| Cocaine-Related Disorders | 1 | 2013 | 82 | 0.400 |
Why?
|
| Intracranial Aneurysm | 1 | 2016 | 345 | 0.400 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 7 | 2020 | 145 | 0.400 |
Why?
|
| Intracranial Hemorrhages | 3 | 2020 | 61 | 0.400 |
Why?
|
| Sulfones | 2 | 2009 | 36 | 0.390 |
Why?
|
| Recovery of Function | 7 | 2020 | 270 | 0.390 |
Why?
|
| Hospital Units | 1 | 2011 | 8 | 0.390 |
Why?
|
| Cohort Studies | 7 | 2019 | 2374 | 0.380 |
Why?
|
| Leukoaraiosis | 3 | 2019 | 44 | 0.380 |
Why?
|
| Colonoscopy | 1 | 2012 | 86 | 0.370 |
Why?
|
| Brain Damage, Chronic | 1 | 2011 | 5 | 0.370 |
Why?
|
| Inpatients | 1 | 2014 | 291 | 0.370 |
Why?
|
| Hospitals | 1 | 2014 | 375 | 0.360 |
Why?
|
| Vertebrobasilar Insufficiency | 2 | 2012 | 23 | 0.360 |
Why?
|
| Stents | 2 | 2013 | 461 | 0.350 |
Why?
|
| Internship and Residency | 2 | 2008 | 746 | 0.340 |
Why?
|
| Educational Measurement | 2 | 2008 | 211 | 0.320 |
Why?
|
| Cerebral Cortex | 1 | 2011 | 248 | 0.320 |
Why?
|
| Neurology | 3 | 2020 | 33 | 0.320 |
Why?
|
| Troponin | 2 | 2019 | 36 | 0.320 |
Why?
|
| Anticoagulants | 4 | 2019 | 477 | 0.320 |
Why?
|
| Mortality | 2 | 2021 | 155 | 0.310 |
Why?
|
| Prognosis | 7 | 2020 | 1600 | 0.310 |
Why?
|
| Neurophysiology | 1 | 2008 | 7 | 0.300 |
Why?
|
| Clinical Medicine | 1 | 2008 | 15 | 0.300 |
Why?
|
| Video Games | 1 | 2008 | 12 | 0.300 |
Why?
|
| Embolism, Paradoxical | 1 | 2008 | 13 | 0.300 |
Why?
|
| Foramen Ovale, Patent | 1 | 2008 | 13 | 0.290 |
Why?
|
| Mass Screening | 1 | 2013 | 645 | 0.290 |
Why?
|
| Intracranial Embolism | 3 | 2017 | 39 | 0.280 |
Why?
|
| Young Adult | 6 | 2019 | 4267 | 0.280 |
Why?
|
| Recurrence | 4 | 2016 | 603 | 0.280 |
Why?
|
| Spinal Puncture | 1 | 2007 | 15 | 0.270 |
Why?
|
| Acute Disease | 3 | 2014 | 660 | 0.270 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2007 | 30 | 0.270 |
Why?
|
| Whole Genome Sequencing | 2 | 2024 | 63 | 0.270 |
Why?
|
| Brain Stem Infarctions | 1 | 2006 | 4 | 0.260 |
Why?
|
| Needles | 1 | 2007 | 65 | 0.260 |
Why?
|
| Pons | 1 | 2006 | 15 | 0.260 |
Why?
|
| Quadriplegia | 1 | 2006 | 14 | 0.260 |
Why?
|
| Smoking Cessation | 3 | 2018 | 541 | 0.260 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2007 | 54 | 0.260 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2016 | 178 | 0.260 |
Why?
|
| Age Factors | 6 | 2020 | 1504 | 0.250 |
Why?
|
| Ventricular Function, Left | 2 | 2018 | 257 | 0.250 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 1025 | 0.250 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2016 | 21 | 0.250 |
Why?
|
| Piracetam | 1 | 2005 | 8 | 0.250 |
Why?
|
| Hyponatremia | 1 | 2005 | 13 | 0.240 |
Why?
|
| Logistic Models | 7 | 2018 | 1232 | 0.240 |
Why?
|
| Pandemics | 4 | 2023 | 615 | 0.240 |
Why?
|
| Hospitalization | 4 | 2020 | 1290 | 0.240 |
Why?
|
| Anticonvulsants | 1 | 2005 | 88 | 0.230 |
Why?
|
| Clinical Protocols | 1 | 2005 | 135 | 0.230 |
Why?
|
| Thalamus | 2 | 2016 | 64 | 0.230 |
Why?
|
| Curriculum | 1 | 2008 | 558 | 0.220 |
Why?
|
| Betacoronavirus | 3 | 2020 | 166 | 0.220 |
Why?
|
| Epilepsy | 1 | 2005 | 105 | 0.220 |
Why?
|
| Hypercholesterolemia | 2 | 2014 | 68 | 0.220 |
Why?
|
| Heart Atria | 2 | 2017 | 135 | 0.210 |
Why?
|
| Cerebral Angiography | 4 | 2017 | 280 | 0.210 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 277 | 0.210 |
Why?
|
| Adult | 13 | 2019 | 15669 | 0.200 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 2 | 2020 | 7 | 0.200 |
Why?
|
| Ischemia | 2 | 2019 | 199 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2022 | 8 | 0.200 |
Why?
|
| Carotid Artery, Common | 1 | 2002 | 30 | 0.190 |
Why?
|
| United States | 10 | 2020 | 7390 | 0.190 |
Why?
|
| Health Services Needs and Demand | 2 | 2020 | 203 | 0.190 |
Why?
|
| Rehabilitation Centers | 1 | 2021 | 12 | 0.190 |
Why?
|
| Carotid Artery Diseases | 1 | 2002 | 63 | 0.190 |
Why?
|
| Venous Thromboembolism | 2 | 2014 | 141 | 0.180 |
Why?
|
| Eggs | 1 | 2021 | 7 | 0.180 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 902 | 0.180 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 3 | 0.180 |
Why?
|
| Oxygen | 2 | 2014 | 313 | 0.180 |
Why?
|
| Genetic Loci | 1 | 2021 | 107 | 0.180 |
Why?
|
| Biomarkers | 2 | 2024 | 1306 | 0.180 |
Why?
|
| Cholesterol, Dietary | 1 | 2021 | 28 | 0.180 |
Why?
|
| Incidence | 6 | 2020 | 1237 | 0.180 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 441 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 1 | 2021 | 83 | 0.180 |
Why?
|
| Myocardial Infarction | 3 | 2019 | 862 | 0.180 |
Why?
|
| Risk Assessment | 6 | 2020 | 1921 | 0.170 |
Why?
|
| Precision Medicine | 1 | 2021 | 102 | 0.170 |
Why?
|
| Databases, Factual | 4 | 2020 | 813 | 0.170 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2021 | 489 | 0.170 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 283 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.170 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 297 | 0.170 |
Why?
|
| Phosphodiesterase Inhibitors | 3 | 2009 | 27 | 0.160 |
Why?
|
| Thrombosis | 1 | 2002 | 182 | 0.160 |
Why?
|
| Retinal Artery Occlusion | 1 | 2019 | 5 | 0.160 |
Why?
|
| Cyclic GMP | 3 | 2009 | 28 | 0.160 |
Why?
|
| Vitamin K | 1 | 2019 | 14 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 31 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 631 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2021 | 3067 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 439 | 0.160 |
Why?
|
| Global Health | 1 | 2020 | 167 | 0.160 |
Why?
|
| Drug Therapy, Combination | 3 | 2012 | 452 | 0.160 |
Why?
|
| Sweetening Agents | 1 | 2019 | 21 | 0.160 |
Why?
|
| Embolism | 1 | 2019 | 39 | 0.160 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 134 | 0.160 |
Why?
|
| Mechanical Thrombolysis | 1 | 2019 | 35 | 0.160 |
Why?
|
| Leukoencephalopathies | 1 | 2019 | 24 | 0.150 |
Why?
|
| Women's Health | 2 | 2019 | 360 | 0.150 |
Why?
|
| Sex Factors | 3 | 2019 | 935 | 0.150 |
Why?
|
| Spinal Cord | 2 | 2016 | 195 | 0.150 |
Why?
|
| Beverages | 1 | 2019 | 66 | 0.150 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 104 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1093 | 0.150 |
Why?
|
| Sildenafil Citrate | 2 | 2009 | 11 | 0.150 |
Why?
|
| Activities of Daily Living | 2 | 2019 | 289 | 0.150 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2016 | 93 | 0.150 |
Why?
|
| Purines | 2 | 2009 | 38 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 676 | 0.150 |
Why?
|
| Rhode Island | 2 | 2016 | 97 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 806 | 0.140 |
Why?
|
| White Matter | 1 | 2019 | 114 | 0.140 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 7 | 0.140 |
Why?
|
| Functional Laterality | 2 | 2016 | 133 | 0.140 |
Why?
|
| Radiography | 2 | 2019 | 517 | 0.140 |
Why?
|
| Weight Gain | 1 | 2018 | 163 | 0.140 |
Why?
|
| Demyelinating Diseases | 1 | 1997 | 16 | 0.140 |
Why?
|
| Vacuoles | 1 | 1997 | 26 | 0.140 |
Why?
|
| Atrial Function, Right | 1 | 2017 | 1 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2018 | 158 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2513 | 0.140 |
Why?
|
| Hospital Mortality | 5 | 2020 | 841 | 0.140 |
Why?
|
| Telemetry | 1 | 2017 | 19 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2017 | 41 | 0.140 |
Why?
|
| Atrial Flutter | 1 | 2017 | 21 | 0.140 |
Why?
|
| Hospital Administration | 1 | 2017 | 41 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2018 | 85 | 0.140 |
Why?
|
| Disability Evaluation | 4 | 2019 | 199 | 0.140 |
Why?
|
| Stroke Volume | 1 | 2018 | 314 | 0.140 |
Why?
|
| Headache Disorders, Primary | 1 | 2016 | 4 | 0.130 |
Why?
|
| Alcohol Abstinence | 1 | 2016 | 10 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 192 | 0.130 |
Why?
|
| Spinal Cord Diseases | 1 | 1997 | 39 | 0.130 |
Why?
|
| Vasospasm, Intracranial | 1 | 2016 | 25 | 0.130 |
Why?
|
| Brain Diseases | 1 | 1997 | 71 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 206 | 0.130 |
Why?
|
| Motor Activity | 1 | 2019 | 333 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2018 | 143 | 0.130 |
Why?
|
| Dura Mater | 1 | 2016 | 33 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 408 | 0.130 |
Why?
|
| Systole | 1 | 2016 | 109 | 0.130 |
Why?
|
| Carbolines | 2 | 2025 | 9 | 0.130 |
Why?
|
| Heart Arrest | 1 | 2018 | 161 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 110 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2016 | 123 | 0.120 |
Why?
|
| Registries | 5 | 2020 | 801 | 0.120 |
Why?
|
| Heart Rate | 1 | 2017 | 307 | 0.120 |
Why?
|
| Cognition | 1 | 2019 | 455 | 0.120 |
Why?
|
| Aneurysm, Ruptured | 1 | 2016 | 71 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 121 | 0.120 |
Why?
|
| Cerebral Infarction | 3 | 2016 | 76 | 0.120 |
Why?
|
| Decompressive Craniectomy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Brain Death | 1 | 2014 | 16 | 0.120 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 2 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2014 | 30 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 43 | 0.120 |
Why?
|
| Neoplasms | 1 | 2025 | 1240 | 0.120 |
Why?
|
| Skull | 1 | 2014 | 50 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2010 | 459 | 0.120 |
Why?
|
| Odds Ratio | 4 | 2017 | 745 | 0.120 |
Why?
|
| Adolescent | 3 | 2016 | 5824 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2017 | 300 | 0.110 |
Why?
|
| Double-Blind Method | 3 | 2020 | 715 | 0.110 |
Why?
|
| Motion Therapy, Continuous Passive | 1 | 2014 | 1 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 206 | 0.110 |
Why?
|
| Hospital Departments | 1 | 2014 | 12 | 0.110 |
Why?
|
| Comorbidity | 3 | 2020 | 1078 | 0.110 |
Why?
|
| Health Literacy | 1 | 2015 | 78 | 0.110 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2004 | 36 | 0.110 |
Why?
|
| Drainage | 1 | 2014 | 149 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 332 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2014 | 53 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 95 | 0.110 |
Why?
|
| Heart Failure | 2 | 2018 | 853 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 788 | 0.110 |
Why?
|
| Alcoholism | 1 | 2016 | 309 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 121 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2014 | 98 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 80 | 0.110 |
Why?
|
| Heparin | 1 | 2014 | 111 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 250 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 170 | 0.100 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2012 | 1 | 0.100 |
Why?
|
| Pupil Disorders | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dysarthria | 1 | 2012 | 7 | 0.100 |
Why?
|
| Apraxias | 1 | 2012 | 7 | 0.100 |
Why?
|
| Acyclovir | 1 | 2012 | 19 | 0.100 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 169 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 306 | 0.100 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2012 | 17 | 0.100 |
Why?
|
| Valine | 1 | 2012 | 31 | 0.100 |
Why?
|
| Cyclophosphamide | 1 | 2012 | 75 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 202 | 0.100 |
Why?
|
| Prednisone | 1 | 2012 | 85 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2012 | 48 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 364 | 0.100 |
Why?
|
| Vision Disorders | 1 | 2012 | 59 | 0.100 |
Why?
|
| Disease Progression | 2 | 2017 | 1122 | 0.100 |
Why?
|
| Cerebral Arteries | 2 | 2009 | 39 | 0.100 |
Why?
|
| Infusions, Intravenous | 3 | 2020 | 164 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2019 | 937 | 0.090 |
Why?
|
| Retinal Vein | 1 | 2011 | 5 | 0.090 |
Why?
|
| Vision, Low | 1 | 2011 | 9 | 0.090 |
Why?
|
| Graves Disease | 1 | 2010 | 15 | 0.090 |
Why?
|
| Echocardiography | 3 | 2018 | 457 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2011 | 119 | 0.090 |
Why?
|
| Retinal Vein Occlusion | 1 | 2011 | 18 | 0.090 |
Why?
|
| Moyamoya Disease | 1 | 2010 | 10 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2010 | 33 | 0.090 |
Why?
|
| Lameness, Animal | 1 | 2010 | 9 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 674 | 0.090 |
Why?
|
| Prevalence | 2 | 2020 | 1252 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 164 | 0.090 |
Why?
|
| Horse Diseases | 1 | 2010 | 22 | 0.090 |
Why?
|
| Interrupted Time Series Analysis | 2 | 2020 | 27 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 157 | 0.090 |
Why?
|
| HIV Infections | 1 | 1997 | 913 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2012 | 260 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 724 | 0.080 |
Why?
|
| Life Style | 1 | 2011 | 299 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 839 | 0.080 |
Why?
|
| Antiviral Agents | 1 | 2012 | 313 | 0.080 |
Why?
|
| Vasodilator Agents | 1 | 2009 | 63 | 0.080 |
Why?
|
| Lipoproteins, HDL | 1 | 2009 | 35 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 2 | 2006 | 101 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2020 | 689 | 0.080 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 110 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2008 | 65 | 0.070 |
Why?
|
| Physical Examination | 1 | 2008 | 104 | 0.070 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 241 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2009 | 140 | 0.070 |
Why?
|
| Snoring | 1 | 2007 | 8 | 0.070 |
Why?
|
| Sleep Stages | 1 | 2007 | 16 | 0.070 |
Why?
|
| Neuropharmacology | 1 | 2007 | 1 | 0.070 |
Why?
|
| Neuroanatomy | 1 | 2007 | 3 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2009 | 170 | 0.070 |
Why?
|
| Group Processes | 1 | 2007 | 41 | 0.070 |
Why?
|
| Europe | 2 | 2017 | 184 | 0.070 |
Why?
|
| Postoperative Period | 1 | 2007 | 127 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2006 | 4 | 0.070 |
Why?
|
| Polysomnography | 1 | 2007 | 55 | 0.070 |
Why?
|
| Magnetoencephalography | 1 | 2006 | 7 | 0.070 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2006 | 8 | 0.070 |
Why?
|
| Manipulation, Chiropractic | 1 | 2006 | 5 | 0.070 |
Why?
|
| Vertebral Artery Dissection | 1 | 2006 | 14 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 1561 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2006 | 31 | 0.060 |
Why?
|
| Stem Cell Transplantation | 1 | 2006 | 75 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2006 | 30 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 515 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2012 | 1202 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2005 | 11 | 0.060 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2005 | 7 | 0.060 |
Why?
|
| Canada | 1 | 2005 | 147 | 0.060 |
Why?
|
| Sodium | 1 | 2005 | 60 | 0.060 |
Why?
|
| Topotecan | 1 | 2025 | 5 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2006 | 141 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2007 | 470 | 0.060 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2025 | 70 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2025 | 97 | 0.060 |
Why?
|
| Molecular Docking Simulation | 1 | 2025 | 73 | 0.060 |
Why?
|
| Patient Selection | 3 | 2017 | 464 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2007 | 249 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2025 | 657 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2007 | 705 | 0.050 |
Why?
|
| Disintegrins | 1 | 2022 | 4 | 0.050 |
Why?
|
| ADAMTS13 Protein | 1 | 2022 | 6 | 0.050 |
Why?
|
| Thrombospondins | 1 | 2022 | 6 | 0.050 |
Why?
|
| Rural Health | 1 | 2002 | 15 | 0.050 |
Why?
|
| Subacute Care | 1 | 2021 | 9 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2021 | 914 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 77 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2003 | 187 | 0.040 |
Why?
|
| Iran | 1 | 2020 | 6 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 1370 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 847 | 0.040 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 25 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 115 | 0.040 |
Why?
|
| Placebo Effect | 1 | 2020 | 10 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 109 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 21 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 2020 | 37 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 331 | 0.040 |
Why?
|
| Health Resources | 1 | 2020 | 87 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 210 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 94 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2020 | 156 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 187 | 0.040 |
Why?
|
| Angiography | 1 | 2019 | 146 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2021 | 254 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 52 | 0.040 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2018 | 7 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2020 | 137 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2019 | 71 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 244 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 249 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2019 | 356 | 0.040 |
Why?
|
| Argentina | 1 | 2017 | 7 | 0.040 |
Why?
|
| North America | 1 | 2017 | 106 | 0.040 |
Why?
|
| Venules | 1 | 1997 | 8 | 0.040 |
Why?
|
| Patient Admission | 1 | 2019 | 184 | 0.040 |
Why?
|
| Italy | 1 | 2017 | 63 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2020 | 256 | 0.030 |
Why?
|
| Serum Albumin | 1 | 2017 | 45 | 0.030 |
Why?
|
| Latin America | 1 | 2017 | 12 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 371 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2017 | 43 | 0.030 |
Why?
|
| Algorithms | 2 | 2016 | 976 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 221 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 409 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 741 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 13 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 423 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 146 | 0.030 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2016 | 30 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2016 | 56 | 0.030 |
Why?
|
| Embolectomy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2009 | 2337 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2006 | 179 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 802 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 555 | 0.030 |
Why?
|
| Observer Variation | 2 | 2006 | 205 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 521 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1189 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2016 | 73 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2019 | 831 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2016 | 114 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2002 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 111 | 0.030 |
Why?
|
| Critical Illness | 1 | 2017 | 325 | 0.030 |
Why?
|
| Health Education | 1 | 2015 | 182 | 0.030 |
Why?
|
| Brain Injuries | 1 | 2014 | 135 | 0.030 |
Why?
|
| Rats | 2 | 2006 | 1910 | 0.030 |
Why?
|
| Pupil | 1 | 2011 | 9 | 0.020 |
Why?
|
| Paresis | 1 | 2010 | 15 | 0.020 |
Why?
|
| Confusion | 1 | 2010 | 16 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Antithyroid Agents | 1 | 2010 | 18 | 0.020 |
Why?
|
| Toe Phalanges | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thyroidectomy | 1 | 2010 | 31 | 0.020 |
Why?
|
| Ligaments | 1 | 2010 | 11 | 0.020 |
Why?
|
| Tendons | 1 | 2010 | 23 | 0.020 |
Why?
|
| Horses | 1 | 2010 | 52 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 177 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 179 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2373 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 130 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 485 | 0.020 |
Why?
|
| Tadalafil | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Ferrocyanides | 1 | 2006 | 1 | 0.020 |
Why?
|
| Anisotropy | 1 | 2006 | 58 | 0.020 |
Why?
|
| Nerve Fibers | 1 | 2006 | 29 | 0.020 |
Why?
|
| Microcirculation | 1 | 2006 | 52 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2006 | 136 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 325 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2006 | 142 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2006 | 92 | 0.020 |
Why?
|
| Animals | 3 | 2010 | 19651 | 0.020 |
Why?
|
| Axons | 1 | 2006 | 118 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 68 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 191 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2006 | 173 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2006 | 215 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 677 | 0.010 |
Why?
|
| Decision Making | 1 | 2008 | 395 | 0.010 |
Why?
|
| Stem Cells | 1 | 2006 | 255 | 0.010 |
Why?
|
| Nervous System | 1 | 2004 | 69 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 298 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 654 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2006 | 942 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2004 | 461 | 0.010 |
Why?
|
| Ontario | 1 | 2002 | 43 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 155 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2002 | 111 | 0.010 |
Why?
|
| Transportation of Patients | 1 | 2002 | 42 | 0.010 |
Why?
|
| Linear Models | 1 | 2002 | 402 | 0.010 |
Why?
|
| Neurons | 1 | 2006 | 863 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2050 | 0.010 |
Why?
|